Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial
N = 1,630
- Population
- Healthy H. pylori carriers in a high-risk region of China (Fujian Province).
- Design
- Prospective, randomised, placebo-controlled, population-based primary prevention study of 1630 healthy H. pylori carriers in Fujian Province, China, recruited from July 1994 and followed until January 2002. Eradication arm: 2 weeks of omeprazole, amoxicillin-clavulanate and metronidazole (n = 817); placebo (n = 813). 988 participants had no precancerous lesions at entry. Primary outcome: gastric cancer incidence. No registry identifier appears in the abstract.
- Primary endpoint
- Gastric cancer incidence
- Arms
- Placebo (control, n = 813): Placebo
- H. pylori eradication (experimental, n = 817): Omeprazole 20 mg, amoxicillin-clavulanate 750 mg and metronidazole 400 mg, all twice daily for two weeks
- People
- Wong BC, senior author China Gastric Cancer Study Group